5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Daiichinkyo Co's 5-Year ROIIC % for the quarter that ended in Mar. 2024 was 13.60%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Daiichinkyo Co's 5-Year ROIIC % or its related term are showing as below:
DSNKY's 5-Year ROIIC % is ranked better than 67.54% of 998
companies
in the Drug Manufacturers industry
Industry Median: 3.765
vs DSNKY: 13.60
Daiichinkyo Co 5-Year ROIIC % Historical Data
The historical data trend for Daiichinkyo Co's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Daiichinkyo Co's 5-Year ROIIC %
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co's 5-Year ROIIC % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's 5-Year ROIIC % falls into.
Daiichinkyo Co 5-Year ROIIC % Calculation
Daiichinkyo Co's 5-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Daiichinkyo Co (OTCPK:DSNKY) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Daiichinkyo Co 5-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of Daiichinkyo Co's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Daiichinkyo Co (Daiichinkyo Co) Business Description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DSNKY has been successfully added to your 